FI944412A0 - Proteiinin puhdistus - Google Patents

Proteiinin puhdistus

Info

Publication number
FI944412A0
FI944412A0 FI944412A FI944412A FI944412A0 FI 944412 A0 FI944412 A0 FI 944412A0 FI 944412 A FI944412 A FI 944412A FI 944412 A FI944412 A FI 944412A FI 944412 A0 FI944412 A0 FI 944412A0
Authority
FI
Finland
Prior art keywords
protein purification
purification
application
relates
receptor proteins
Prior art date
Application number
FI944412A
Other languages
English (en)
Swedish (sv)
Other versions
FI109202B (fi
FI944412A (fi
Inventor
Gail Folena-Wasserman
John H O'grady
Thomas M Smith
John Lifter
Original Assignee
Smithkline Beecham Corp
T Cell Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, T Cell Sciences Inc filed Critical Smithkline Beecham Corp
Publication of FI944412A0 publication Critical patent/FI944412A0/fi
Publication of FI944412A publication Critical patent/FI944412A/fi
Application granted granted Critical
Publication of FI109202B publication Critical patent/FI109202B/fi

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size selective separation, e.g. size exclusion chromatography, gel filtration, permeation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI944412A 1992-03-24 1994-09-23 Proteiinin puhdistus FI109202B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/857,022 US5252216A (en) 1992-03-24 1992-03-24 Protein purification
US85702292 1992-03-24
PCT/US1993/002732 WO1993018835A1 (en) 1992-03-24 1993-03-24 Protein purification
US9302732 1993-03-24

Publications (3)

Publication Number Publication Date
FI944412A0 true FI944412A0 (fi) 1994-09-23
FI944412A FI944412A (fi) 1994-09-23
FI109202B FI109202B (fi) 2002-06-14

Family

ID=25324998

Family Applications (1)

Application Number Title Priority Date Filing Date
FI944412A FI109202B (fi) 1992-03-24 1994-09-23 Proteiinin puhdistus

Country Status (19)

Country Link
US (1) US5252216A (fi)
EP (1) EP0643608B1 (fi)
JP (1) JP3335629B2 (fi)
KR (1) KR100241172B1 (fi)
AT (1) ATE193839T1 (fi)
AU (1) AU659936B2 (fi)
CA (1) CA2132533C (fi)
DE (1) DE69328864T2 (fi)
DK (1) DK0643608T3 (fi)
ES (1) ES2149206T3 (fi)
FI (1) FI109202B (fi)
GR (1) GR3034332T3 (fi)
MX (1) MX9301655A (fi)
NO (1) NO310855B1 (fi)
NZ (1) NZ251601A (fi)
PT (1) PT643608E (fi)
TW (1) TW321651B (fi)
WO (1) WO1993018835A1 (fi)
ZA (1) ZA932015B (fi)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
DE4331358A1 (de) * 1992-10-12 1994-04-14 Braun Melsungen Ag Verfahren zur quantitativen selektiven Entfernung oder präparativen Gewinnung von Tumor-Nekrose-Faktor (TNF) oder/und Lipopolysacchariden (LPS) aus wäßrigen Flüssigkeiten
JPH08512323A (ja) * 1993-07-09 1996-12-24 スミスクライン・ビーチャム・コーポレイション タンパク精製方法
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
DE19515554C2 (de) * 1995-04-27 1999-06-17 Braun Melsungen Ag Verwendung eines Mittels und Vorrichtung zur simultanen extrakorporalen Elimination von Tumor-Nekrose-Faktor alpha und bakteriellen Lipopolysacchariden aus Vollblut oder/und Blutplasma
EP1300679A3 (en) * 1995-06-26 2004-04-14 Perseptive Biosystems, Inc. Molecular selection and analysis
WO1997001755A2 (en) * 1995-06-26 1997-01-16 Perseptive Biosystems, Inc. High speed, automated, continuous flow, multi-dimensional molecular selection and analysis
GB9515196D0 (en) * 1995-07-25 1995-09-20 Matthey Rustenburg Refines Interseparation of platignum group metals
JP2002511147A (ja) * 1997-06-27 2002-04-09 ライフ テクノロジーズ インク． 生体分子の濃縮および精製のための一工程装置および方法
US5993653C1 (en) * 1997-08-11 2001-11-06 Phenomenex Composition and column used in hplc
US6869796B2 (en) * 1997-08-26 2005-03-22 Avaris Ab Method of introducing organic molecules into target cells
US20070122904A1 (en) * 2000-09-29 2007-05-31 Unisearch Limited Method and apparatus for culturing cells
US6855263B2 (en) * 2002-07-23 2005-02-15 Nuvue Technologies, Inc. Rapid process for purification and concentration of plasmin
DE10255508A1 (de) * 2002-11-27 2004-06-17 Forschungszentrum Jülich GmbH Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen
US6913695B2 (en) * 2003-07-08 2005-07-05 Bayer Healthcare Llc Sanitization of chromatographic media
WO2005012349A2 (en) * 2003-08-01 2005-02-10 Lorantis Limited Chromatographic process for the purification of notch ligands
WO2005073732A2 (en) * 2004-01-23 2005-08-11 Amgen Inc. Lc/ms method of analyzing high molecular weight proteins
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
ATE443870T1 (de) * 2004-07-20 2009-10-15 Symphogen As Verfahren zur charakterisierung einer polyklonalen zellinie
US20090042274A1 (en) * 2004-07-27 2009-02-12 Genomidea Inc. Method of Purifying Virus Envelope
WO2006016161A1 (en) * 2004-08-12 2006-02-16 Lipoxen Technologies Limited Fractionation of charged polysaccharide
EP1738763A1 (en) 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Use of complement inhibitory proteins to treat spinal cord injury
WO2007053235A1 (en) * 2005-11-04 2007-05-10 Sachem, Inc. Cation-exchange displacement chromatography process and cationic organic compounds for use as displacer compounds in cation-exchange displacement chromatography process
US20090269356A1 (en) 2006-03-08 2009-10-29 David Epstein Complement Binding Aptamers and Anti-C5 Agents Useful in the Treatment of Ocular Disorders
US20100222560A1 (en) 2009-03-02 2010-09-02 Zymo Research Corporation Universal column
HUE033758T2 (en) 2009-10-26 2017-12-28 Hoffmann La Roche A method for producing glycosylated immunoglobulin
CN107661491A (zh) 2010-09-15 2018-02-06 赛尔戴克斯治疗公司 用可溶性I型补体受体(sCR1)治疗慢性肾病
US9677042B2 (en) 2010-10-08 2017-06-13 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
BR112013010098A2 (pt) 2010-10-27 2017-06-13 Celldex Therapeutics Inc método para melhorar a função de transplante usando um receptor do complemento solúvel tipo i (scr1)
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
JP7034949B2 (ja) 2016-05-25 2022-03-14 テルモ ビーシーティー、インコーポレーテッド 細胞の増殖
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US11702634B2 (en) 2017-03-31 2023-07-18 Terumo Bct, Inc. Expanding cells in a bioreactor
WO2023240322A1 (en) * 2022-06-17 2023-12-21 CSL Innovation Pty Ltd Purification of soluble complement receptor and variants thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2319495C2 (de) * 1973-04-17 1985-01-10 Yeda Research And Development Co., Ltd., Rehovot Verfahren zum selektiven, reversiblen Binden von Biomolekülen an ein Adsorbens in einer chromatographischen Säule
US4000098A (en) * 1974-08-16 1976-12-28 Palo Alto Medical Research Foundation Separation of proteins by hydrophobic adsorption
DE3149360A1 (de) * 1981-12-12 1983-06-16 Biotest-Serum-Institut Gmbh, 6000 Frankfurt "verfahren zur reinigung und/oder phytohaemagglutinin-abtrennung von human-interleukin-2"
US4920196A (en) * 1982-07-30 1990-04-24 Genentech, Inc. Human lymphotoxin
US4908434A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Process for preparing purified interleukin-2
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
AU597924B2 (en) * 1985-12-11 1990-06-14 Natinco Nv Solubilization of protein aggregates
US4770781A (en) * 1986-03-03 1988-09-13 Merck & Co., Inc. Purification of human interleukin-1 species
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
AU609824B2 (en) * 1987-06-15 1991-05-09 Southern Cross Biotech Pty Ltd. Production of proteins in active forms
US4981799A (en) * 1987-08-21 1991-01-01 Takeda Chemical Industries, Ltd. Acylamino acid racemase, production and use thereof
US4765903A (en) * 1987-10-06 1988-08-23 Interferon Sciences, Inc. Purification of monomeric interferon
US5159063A (en) * 1989-02-02 1992-10-27 The United States Of America As Represented By The Department Of Health And Human Services Isolation and characterization of a 120 kda glycoprotein plasma
US5030352A (en) * 1990-01-25 1991-07-09 Purdue Research Foundation Coated media for chromatography

Also Published As

Publication number Publication date
NO310855B1 (no) 2001-09-10
KR950700779A (ko) 1995-02-20
NO943546L (no) 1994-11-23
NZ251601A (en) 1997-03-24
EP0643608B1 (en) 2000-06-14
WO1993018835A1 (en) 1993-09-30
EP0643608A1 (en) 1995-03-22
PT643608E (pt) 2000-11-30
JP3335629B2 (ja) 2002-10-21
JPH07505469A (ja) 1995-06-15
DE69328864D1 (de) 2000-07-20
DK0643608T3 (da) 2000-10-02
AU3932493A (en) 1993-10-21
CA2132533A1 (en) 1993-09-30
AU659936B2 (en) 1995-06-01
TW321651B (fi) 1997-12-01
NO943546D0 (no) 1994-09-23
US5252216A (en) 1993-10-12
ES2149206T3 (es) 2000-11-01
FI109202B (fi) 2002-06-14
CA2132533C (en) 2004-01-13
FI944412A (fi) 1994-09-23
EP0643608A4 (en) 1997-11-26
DE69328864T2 (de) 2000-12-14
ATE193839T1 (de) 2000-06-15
ZA932015B (en) 1994-09-21
MX9301655A (es) 1994-03-31
GR3034332T3 (en) 2000-12-29
KR100241172B1 (ko) 2000-02-01

Similar Documents

Publication Publication Date Title
DK0643608T3 (da) Proteinrensning
DK0746398T3 (da) Antistofrensning
BR9808934A (pt) Proteìnas de fusão de região constante de receptor/imunoglobulina tgf-beta do tipo ii
DE69430016D1 (de) Proteinreinigung
ES2076999T3 (es) Peptidos anticoagulantes radiomarcados.
DK0538754T3 (da) Anvendelse af antistofholdige præparater til immunundertrykkelse
DE69032258D1 (de) Antikoagulierende Peptide
ITRM920658A0 (it) Procedimento per la purificazione della proteina endotelina
ES2131041T3 (es) Peptidos anticoagulantes.
DK0540574T3 (da) Antikoagulationspeptider
IT8921396A0 (it) Procedimento per la sintesi di peptidi preventivamente identificati come siti di interazione di proteine interagenti.

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: SMITHKLINE BEECHAM CORPORATION

MA Patent expired